AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2019

Mar 11, 2019

30610_dirs_2019-03-11_689bff37-1e9b-4e70-b58c-8cd95f706d93.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2019-03-08

Reporting Person: HENDERSON LORI M. (General Counsel and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-08	Stock Option (Right to Buy)	$20.93	A	186092	Acquired	2029-03-08	Common Stock (186092)	Direct

Footnotes

F1: 25% of this option will vest and become exercisable on March 8, 2020 with the remainder vesting in twelve (12) equal quarterly installments thereafter.